Compare JOUT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JOUT | CBIO |
|---|---|---|
| Founded | 1970 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.3M | 537.5M |
| IPO Year | 1994 | 2013 |
| Metric | JOUT | CBIO |
|---|---|---|
| Price | $44.77 | $14.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 30.4K | ★ 363.2K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $592,415,000.00 | $18,500.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $3.70 | $279.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.65 | $8.72 |
| 52 Week High | $53.54 | $27.41 |
| Indicator | JOUT | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 32.69 |
| Support Level | $43.02 | $9.95 |
| Resistance Level | $48.01 | $18.53 |
| Average True Range (ATR) | 1.32 | 1.40 |
| MACD | -0.01 | -0.62 |
| Stochastic Oscillator | 11.48 | 7.09 |
Johnson Outdoors Inc is a manufacturer and marketer of branded seasonal, outdoor recreation products used for fishing from a boat, diving, paddling, hiking and camping. The company has four operating segment: Fishing, Camping, Watercraft Recreation, and Diving. It generates maximum revenue from the Fishing segment which produces and markets products under different brands such as Minn Kota electric motors for quiet trolling or primary propulsion, marine battery chargers and shallow water anchors; Humminbird sonar and GPS equipment for fish finding, navigation and marine cartography; and Cannon downriggers for controlled-depth fishing. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe, Canada, and other regions.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.